News|Articles|October 13, 2026

Most Adolescents With Colorectal Cancer Diagnosed at Advanced Stage, Study Finds

Fact checked by: Abigail Brooks, MA

Most adolescents with sporadic colorectal cancer present with stage III or IV disease, and few have a family history, per data presented at AAP 2026.

Adolescents and young adults with sporadic colorectal cancer (CRC) most often present with stage III or IV disease, and only about 1 in 5 have a family history of the disease, according to a multi-institutional study presented at the American Academy of Pediatrics (AAP) 2026 National Conference & Exhibition in San Diego.1,2

The findings add to growing concern about early-onset CRC and suggest that symptoms such as abdominal pain and rectal bleeding in younger patients may be dismissed because the disease is rare in this age group.1

"Colorectal cancer is, unfortunately, becoming more common in adolescents and young adults and represents a different disease than colorectal cancer diagnosed in older adults," coauthor Erica Arnold, MD, a pediatric surgery research fellow, said in a press release. “When diagnosed, it is often aggressive, presenting with late-stage disease and associated with high rates of disease relapse and mortality.”1

Researchers with the Pediatric Surgical Oncology Research Collaborative retrospectively reviewed records of patients aged 21 years or younger diagnosed with CRC between 2012 and 2023 at 34 institutions. Patients with a known CRC predisposition syndrome, including genetic syndromes and inflammatory bowel disease, were excluded.2

The cohort included 84 patients. Median age at diagnosis was 16.5 years (IQR, 14.0-19.0), and 56.0% were male. Colon adenocarcinoma accounted for 77.4% of cases and rectal adenocarcinoma for 22.6%; among colon cancers, the sigmoid and ascending colon were the most common sites (27.7% each).2

Common presenting symptoms

The most frequently reported symptoms at presentation were:<sup>2</sup>

  • Back or abdominal pain (73.8%)
  • Change in bowel habits (45.2%)
  • Weight loss (42.9%)
  • Rectal bleeding (38.1%)

Patients had symptoms for a median of 12 weeks (IQR, 2.0-24.0) before diagnosis, and median time to colonoscopy was 13 weeks (IQR, 6.0-32.0). Only 20.2% reported a first- or second-degree relative with CRC.2

Advanced disease and aggressive histology

Most patients presented with locally advanced or metastatic disease: 51.0% had stage III and 29.0% had stage IV CRC at diagnosis. Upfront resection was performed in 73.8% of patients, while 17.9% received neoadjuvant chemotherapy.2

Pathology frequently showed high-risk features, including signet ring cells (33.3%), mucin (39.3%), and poorly differentiated histology (41.6%). Of the 46 patients who underwent germline testing, 17.4% had a mismatch repair mutation, 8.6% a TP53 mutation, and 4.3% an APC mutation.2

High rates of relapse and mortality

Overall, 36.9% of participants experienced relapse at a median of 11 months (IQR, 10.0-21.0), and nearly all of them (96.8%) had stage III or IV disease at diagnosis. Compared with patients who did not relapse, those who did were more likely to have2:

  • Positive lymph nodes (90.3% vs 50.9%; P = .0004)
  • Poorly differentiated histology (64.5% vs 28.3%; P = .0047)
  • Signet ring features (61.3% vs 17.0%; P = .0002)

By the end of the study period, 45.2% of patients had died of CRC.2 The authors noted that diagnostic delays, combined with aggressive tumor biology, may contribute to poor long-term outcomes.1

Implications for frontline clinicians

The investigators concluded that practitioners should consider CRC in the differential diagnosis for adolescents with symptoms such as abdominal pain and rectal bleeding when no alternative diagnosis explains them. Because most patients in the study had no known family history, a negative family history should not by itself rule out further evaluation in your patients.2

The authors also emphasized taking unexplained weight loss and rectal bleeding seriously in younger patients. As early-onset cancers appear in increasingly younger patients, they noted that coordination between pediatric and adult care teams and carefully tailored treatment regimens will be essential.2

The findings were presented as a conference abstract and have not yet been published as a full peer-reviewed study.

References:

  1. American Academy of Pediatrics. Colorectal cancer on the rise in adolescent patients. News release. October 2, 2026. Accessed October 13, 2026.
  2. Arnold E, Cameron D, et al. Clinical presentation and epidemiology of pediatric and adolescent colorectal carcinoma: a Pediatric Surgical Oncology Research Collaborative study. Abstract presented at: American Academy of Pediatrics 2026 National Conference & Exhibition; October 3, 2026; San Diego, CA. Abstract text in AAP news release.

Related to this article